X

Blood

Blood
Treatment Dependence of Prognostic Gene Expression Signatures in de novo Follicular Lymphoma

Study investigators evaluate the performance and treatment dependence of the published gene expression–based models in patients with first-line FL treated in the randomized, phase 3 GALLIUM study..

Blood
05/13/2021
miR-29 Modulates CD40 Signaling in Chronic Lymphocytic Leukemia by Targeting TRAF4: An Axis Affected by BCR Inhibitors

miR-29 down-modulation in an intraclonal CLL subpopulation from immune niches allows for higher TRAF4 and increased CD40 responsiveness.

Blood
05/06/2021
miR-15a/16-1 Deletion in Activated B Cells Promotes Plasma Cell and Mature B-Cell Neoplasms

Upon BCR antigen stimulation, follicular B cells undergo T-cell–dependent activation, whereas marginal zone and B1 B cells undergo mainly T-cell–independent activation.

Blood
04/08/2021
Ivosidenib or Enasidenib Combined With Intensive Chemotherapy in Patients With Newly Diagnosed AML

Ivosidenib or enasidenib combined with induction and consolidation chemotherapy were both well tolerated in newly diagnosed mIDH1/2 AML.

Blood
04/01/2021
Isatuximab as Monotherapy and Combined With Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

In myeloma patients with a median 4 prior therapy lines, adding dexamethasone to isatuximab increased response rates from 23.9% to 43.6%.

Blood
03/04/2021
Repurposing a Novel Anti-Cancer RXR Agonist to Attenuate Murine Acute GVHD and Maintain Graft-versus-Leukemia Responses

Study investigators have developed a novel pharmacological approach to inhibit graft-versus-host disease by activating retinoid X receptor in donor T cells.

Blood
02/25/2021
Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia

Flotetuzumab is associated with acceptable safety and evidence of activity in AML patients with PIF/ER.

Blood
02/11/2021
Efficacy and Safety Results from CheckMate 140, A Phase 2 Study of Nivolumab For Relapsed/Refractory Follicular Lymphoma

Nivolumab showed promising activity in R/R FL in a phase 1 study.

Blood
02/04/2021
A Phase 2 Study of Venetoclax Plus R-CHOP as First-Line Treatment for Patients With Diffuse Large B-Cell Lymphoma

Venetoclax + R-CHOP showed potential for improved efficacy vs R-CHOP alone, supporting further investigation of venetoclax in Bcl-2+ DLBCL.

Blood
02/04/2021
Primum Non Nocere: Allo-HSCT for AML in CR1

This study demonstrates the potential applicability of a knowledge bank to inform decision making as to whether patients ages 18 to 59 years with AML should undergo allogeneic HSCT...

Blood
01/28/2021
Subscribe to Blood

source list reference

#7d60d9
#2694a4
#32a887
#85eb24
#352625
#4d4537
#d2093c
#8e3f1c
#76b6c3
#bfcfc8
#c61417
#67e25b
#efef71
#03cffc
#42fc9a
#cc529a
#c59445
#c8cc0c
#bf6be3
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
#a153ac
#e7f6e3
#6fc969
#9a8c2c
#a9c507
#2b9ab3
#e61923
#990677
#4a7bab
#89f67c
#49a21d
#2c990a
#d7da81
#f5ce42
#575662
#a60538
#49cde9
#c20fce
#d95d39
#eb5834